半剂量阿替普酶药物介入策略对比直接PCI治疗STEMI的疗效与安全性:EARLY-MYO试验
EARLY-MYO试验为前瞻性多中心随机非劣效研究,纳入344例症状发作≤6小时且预期PCI延迟的STEMI患者,比较半剂量阿替普酶药物介入策略与直接PCI。药物介入组完全心外膜和心肌再灌注率更高(34.2%对22.8%,优效性P=0.022),但轻微出血更常见(26.9%对11.0%,P<0.001),30天临床硬终点无显著差异。
要点
- 半剂量阿替普酶药物介入策略在完全再灌注上非劣效且优效于直接PCI。
- 两组30天死亡、再梗死、心衰、大出血及颅内出血无显著差异。
- 药物介入组轻微出血发生率显著更高(26.9%对11.0%)。
核心结论
- 对于症状发作≤6小时且预期PCI延迟的STEMI患者,半剂量阿替普酶药物介入策略较直接PCI提供更完全的完全心外膜和心肌再灌注。
研究设计与样本
- 研究者发起的、前瞻性、多中心、随机、非劣效试验,共纳入7个中心344例18至75岁STEMI患者,随机分为药物介入组(n=171)和直接PCI组(n=173)。
主要发现
- 主要终点(完全心外膜和心肌再灌注)药物介入组34.2%对直接PCI组22.8%,非劣效性P<0.05,优效性P=0.022。
- 主要终点各组分无显著差异:TIMI血流3级91.3%对89.2%(P=0.580),TIMI心肌灌注3级65.8%对62.9%(P=0.730),ST段回落≥70% 50.9%对45.5%(P=0.377)。
- 梗死面积(23.3%±11.3%对25.8%±13.7%,P=0.101)和左心室射血分数(52.2%±11.0%对51.4%±12.0%,P=0.562)两组相似。
- 30天总死亡(0.6%对1.2%,P=1.0)、再梗死(0.6%对0.6%,P=1.0)、心力衰竭(13.5%对16.2%,P=0.545)、大出血(0.6%对0%,P=0.497)及颅内出血(0%对0%)无显著差异,但轻微出血药物介入组更常见(26.9%对11.0%,P<0.001)。
临床怎么用
- 对于症状发作≤6小时且预期PCI延迟的STEMI患者,可考虑半剂量阿替普酶药物介入策略以改善再灌注。
- 应用该策略时需注意轻微出血风险增加。
局限性
- 作者指出需要足够样本量的试验来评估该再灌注策略的临床和安全结局。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Timely primary percutaneous coronary intervention (PPCI) cannot be offered to all patients with ST-segment-elevation myocardial infarction (STEMI). Pharmaco-invasive (PhI) strategy has been proposed as a valuable alternative for eligible patients with STEMI. We conducted a randomized study to compare the efficacy and safety of a PhI strategy with half-dose fibrinolytic regimen versus PPCI in patients with STEMI. METHODS: The EARLY-MYO trial (Early Routine Catheterization After Alteplase Fibrinolysis Versus Primary PCI in Acute ST-Segment-Elevation Myocardial Infarction) was an investigator-initiated, prospective, multicenter, randomized, noninferiority trial comparing a PhI strategy with half-dose alteplase versus PPCI in patients with STEMI 18 to 75 years of age presenting ≤6 hours after symptom onset but with an expected PCI-related delay. The primary end point of the study was complete epicardial and myocardial reperfusion after PCI, defined as thrombolysis in myocardial infarction flow grade 3, thrombolysis in myocardial infarction myocardial perfusion grade 3, and ST-segment resolution ≥70%. We also measured infarct size and left ventricular ejection fraction with cardiac magnetic resonance and recorded 30-day clinical and safety outcomes. RESULTS: A total of 344 patients from 7 centers were randomized to PhI (n=171) or PPCI (n=173). PhI was noninferior (and even superior) to PPCI for the primary end point (34.2% versus 22.8%, Pnoninferiority<0.05, Psuperiority=0.022), with no significant differences in the frequency of the individual components of the combined end point: thrombolysis in myocardial infarction flow 3 (91.3% versus 89.2%, P=0.580), thrombolysis in myocardial infarction myocardial perfusion grade 3 (65.8% versus 62.9%, P=0.730), and ST-segment resolution ≥70% (50.9% versus 45.5%, P=0.377). Infarct size (23.3%±11.3% versus 25.8%±13.7%, P=0.101) and left ventricular ejection fraction (52.2%±11.0% versus 51.4%±12.0%, P=0.562) were similar in both groups. No significant differences occurred in 30-day rates of total death (0.6% versus 1.2%, P=1.0), reinfarction (0.6% versus 0.6%, P=1.0), heart failure (13.5% versus 16.2%, P=0.545), major bleeding events (0.6% versus 0%, P=0.497), or intracranial hemorrhage (0% versus 0%), but minor bleeding (26.9% versus 11.0%, P<0.001) was observed more often in the PhI group. CONCLUSIONS: For patients with STEMI presenting ≤6 hours after symptom onset and with an expected PCI-related delay, a PhI strategy with half-dose alteplase and timely PCI offers more complete epicardial and myocardial reperfusion when compared with PPCI. Adequately powered trials with this reperfusion strategy to assess clinical and safety outcomes are warranted. CLINICAL TRIAL REGISTRATION: URL: https://www.clinicaltrials.gov. Unique identifier: NCT01930682.
引用
- Pu J, Ding S, Ge H, et al. Efficacy and Safety of a Pharmaco-Invasive Strategy With Half-Dose Alteplase Versus Primary Angioplasty in ST-Segment-Elevation Myocardial Infarction: EARLY-MYO Trial (Early Routine Catheterization After Alteplase Fibrinolysis Versus Primary PCI in Acute ST-Segment-Elevation Myocardial Infarction). Circulation. 2017. PMID: 28844990. doi:10.1161/CIRCULATIONAHA.117.030582
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。